Last $74.17 USD
Change Today -0.035 / -0.05%
Volume 484.7K
ESRX On Other Exchanges
Symbol
Exchange
ESRX is not on other exchanges.
As of 10:22 AM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

express scripts holding co (ESRX) Snapshot

Open
$73.88
Previous Close
$74.20
Day High
$74.26
Day Low
$73.87
52 Week High
03/11/14 - $79.37
52 Week Low
10/25/13 - $59.20
Market Cap
55.2B
Average Volume 10 Days
4.0M
EPS TTM
$3.13
Shares Outstanding
745.5M
EX-Date
--
P/E TM
23.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for EXPRESS SCRIPTS HOLDING CO (ESRX)

express scripts holding co (ESRX) Details

Express Scripts Holding Company provides a range of pharmacy benefit management (PBM) services primarily in the United States and Canada. The company offers healthcare management and administration services on behalf of its clients. It operates in two segments, PBM and Other Business Operations. The company’s PBM services comprise retail network pharmacy administration; home delivery pharmacy; benefit design consultation; drug utilization review; drug formulary management; clinical solutions to improve health outcomes; an array of Medicare Part D, Medicaid, and health insurance marketplace; specialty pharmacy services, such as the distribution of fertility pharmaceuticals that require special handling or packaging; bio- pharmaceutical services, including reimbursement and logistics solutions; group purchasing organization administration; and consumer health and drug information services. It is also involved in the distribution of pharmaceuticals and medical supplies to providers and clinics; development of scientific evidence to guide the use of medicines; and provision of case management approach to manage care by integrating pre-certification, case management, and discharge planning services for patients. Express Scripts Holding Company provides its PBM services to managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans, and government health programs; and specialty services to managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, government health programs, office-based oncologists, renal dialysis clinics, ambulatory surgery centers, primary care physicians, retina specialists, and others. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in St. Louis, Missouri.

express scripts holding co (ESRX) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.2M
Executive Vice President and General Counsel
Total Annual Compensation: $617.8K
Vice President and Corporate Treasurer
Total Annual Compensation: $486.2K
Executive Vice President of Sales and Marketi...
Total Annual Compensation: $689.6K
Compensation as of Fiscal Year 2013.

express scripts holding co (ESRX) Key Developments

Express Scripts Holding Company Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Revises Earnings Guidance for the Year Ending December 31, 2014; Provides Earnings Guidance for the Third Quarter of 2014

Express Scripts Holding Company reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenues of $25,111.0 million against $26,381.9 million for the same period last year. Operating income was $966 million against $1,004.3 million for the same period last year. Income before income taxes was $841.6 million against $884.8 million for the same period last year. Net income from continuing operations was $522.7 million or $0.67 per diluted share against $574.4 million or $0.68 per diluted share a year ago. Net income attributable to the company was $515.2 million or $0.67 per diluted share against $543 million or $0.66 per diluted share for the same period last year. EBITDA from continuing operations, attributable to the company, as reported was $1,516.6 million against $1,606.2 million a year ago. Adjusted EBITDA from continuing operations, attributable to the company was $1,735.2 million against $1,746.1 million a year ago. Adjusted EBITDA from continuing operations attributable to company per adjusted claim was $5.35 compared to $4.73 a year ago. Adjusted net income attributable to the company was $939.4 million or $1.23 per diluted share against $940.3 million or $1.13 per diluted share for the same period last year. The company generated $735.5 million of cash flow during the quarter. For the six months, the company reported revenues of $48,796.0 million against $52,401.8 million for the same period last year. Operating income was $1,675.2 million against $1,847.4 million for the same period last year. Income before income taxes was $1,437.4 million against $1,523.9 million for the same period last year. Net income from continuing operations was $857.2 million or $1.09 per diluted share against $954.4 million or $1.13 per diluted share a year ago. Net income attributable to the company was $843.5 million or $1.09 per diluted share against $916.0 million or $1.10 per diluted share for the same period last year. Net cash provided by operating activities was $1,189.5 million against $782.5 million for the same period last year. Purchases of property and equipment were $208.8 million against $194.9 million for the same period last year. EBITDA from continuing operations, attributable to the company, as reported was $2,772.7 million against $3,044.5 million a year ago. Adjusted EBITDA from continuing operations, attributable to the company was $3,206.2 million against $3,339 million a year ago. Adjusted EBITDA from continuing operations attributable to company per adjusted claim was $4.97 compared to $4.40 a year ago. Adjusted net income attributable to the company was $1,718.6 million or $2.21 per diluted share against $1,765.5 million or $2.12 per diluted share for the same period last year. For the year ending December 31, 2014, the company provided adjusted earnings per share attributable to the company in the range of $4.84 to $4.92 compared to previous guidance in the range of $4.82 to $4.94. Adjusted EBITDA is expected to be in the range of $6,775 million to $6,925 million compared to previous guidance of $6,775 million to $6,975 million. Adjusted EBITDA attributable to the company per adjusted claim is expected to be in the range of $5.20 to $5.30 compared to previous guidance of $5.20 to $5.30. Cash flow from operations is expected to be in the range of $4,550 million to $5,150 million compared to previous guidance of $4,700 million to $5,300 million. Cash flow from operations is expected to be in the range of $4,550 million to $5,150 million. Effective income tax rate is expected to be between 38.0% to 38.2% compared to previous guidance in the range of 38.0% to 38.5%. Depreciation is expected in the range of $400 million to $420 million compared to previous guidance in the range of $400 million to $420 million. Capital expenditure is expected in the range of $400 million to $450 million compared to previous guidance in the range of $400 million to $450 million. The company said with regards to third quarter projections, earnings per share is expected to be between $1.27 to $1.31, up 22% to 26% year-over-year, excluding UnitedHealth.

Express Scripts Unveiling $56 Million Expansion

Express Scripts Holding Co., will unveil its newest $56 million expansion of its St. Louis headquarters July 28, 2014. The company will be opening a new office building and an addition of an existing building. It received $6.8 million in tax incentives from Missouri to construct the additional building for the promise of adding jobs. If the jobs are created, Express Scripts could be eligible for $24.7 million in additional tax credits. The 220,000-square-foot building sits on Express Scripts' north St. Louis County campus, the St. Louis Business Journal previously reported. The company also added another 10,000 square feet to an existing lab.

Express Scripts Holding Company to Report Q2, 2014 Results on Jul 29, 2014

Express Scripts Holding Company announced that they will report Q2, 2014 results After-Market on Jul 29, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ESRX:US $74.16 USD -0.04

ESRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ESRX.
View Industry Companies
 

Industry Analysis

ESRX

Industry Average

Valuation ESRX Industry Range
No financial data is available for ESRX.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXPRESS SCRIPTS HOLDING CO, please visit www.express-scripts.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.